ZA200100827B - Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure. - Google Patents
Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure.Info
- Publication number
- ZA200100827B ZA200100827B ZA200100827A ZA200100827A ZA200100827B ZA 200100827 B ZA200100827 B ZA 200100827B ZA 200100827 A ZA200100827 A ZA 200100827A ZA 200100827 A ZA200100827 A ZA 200100827A ZA 200100827 B ZA200100827 B ZA 200100827B
- Authority
- ZA
- South Africa
- Prior art keywords
- acute
- renal failure
- receptor
- prostaglandin
- chronic renal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17896800P | 2000-01-31 | 2000-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200100827B true ZA200100827B (en) | 2002-07-30 |
Family
ID=22654657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200100827A ZA200100827B (en) | 2000-01-31 | 2001-01-30 | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6610719B2 (da) |
| EP (1) | EP1132086B1 (da) |
| JP (2) | JP3839261B2 (da) |
| KR (1) | KR100419684B1 (da) |
| AT (1) | ATE327751T1 (da) |
| AU (1) | AU774569B2 (da) |
| CA (1) | CA2332687A1 (da) |
| CO (1) | CO5261529A1 (da) |
| CY (1) | CY1105299T1 (da) |
| DE (1) | DE60120007T2 (da) |
| DK (1) | DK1132086T3 (da) |
| ES (1) | ES2263557T3 (da) |
| HU (1) | HUP0100495A3 (da) |
| IL (1) | IL141120A0 (da) |
| NZ (1) | NZ509632A (da) |
| PE (1) | PE20011048A1 (da) |
| PT (1) | PT1132086E (da) |
| ZA (1) | ZA200100827B (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002024647A1 (fr) * | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
| IL155368A0 (en) | 2000-11-27 | 2003-11-23 | Pfizer Prod Inc | Ep4 receptor selective agonists in the treatment of osteoporosis |
| EP1408961B1 (en) | 2001-07-16 | 2007-07-11 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
| HU230421B1 (hu) * | 2001-07-23 | 2016-05-30 | Ono Pharmaceutical Co., Ltd | Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek |
| DE60226051T2 (de) * | 2001-10-23 | 2009-05-20 | Laboratoires Serono S.A., Coinsins | Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| EP1481976B1 (en) * | 2002-03-05 | 2012-11-07 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| AU2003209571A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US20050239872A1 (en) * | 2002-06-06 | 2005-10-27 | Xavier Billot | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma |
| EP1556347A4 (en) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE |
| EP1563846B1 (en) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| FI20030015A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Menetelmä munuaisten vajaatoiminnan hoitamiseksi |
| WO2004065365A1 (ja) * | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20080306155A1 (en) * | 2004-09-16 | 2008-12-11 | Roman Richard J | Method for treating renal disease |
| US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| EP1952823A1 (en) | 2007-01-30 | 2008-08-06 | AM-Pharma B.V. | The use of alkaline phosphatase in the treatment of reduced renal function |
| WO2010108028A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| AU2011266057B2 (en) | 2010-06-17 | 2014-12-04 | Nitto Denko Corporation | Agent for treating renal fibrosis |
| JP6047489B2 (ja) | 2010-08-12 | 2016-12-21 | フェイト セラピューティクス，インコーポレイテッド | 改善された造血幹細胞および前駆細胞療法 |
| AU2012290987B2 (en) | 2011-08-02 | 2017-04-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
| BR112014007782B1 (pt) | 2011-09-30 | 2021-06-01 | Bluebird Bio, Inc. | Método para aumentar a eficiência de transdução lentiviral de células progenitoras ou células-tronco hematopoiéticas cd34+, bem como usos terapêuticos de composição compreendendo as ditas células e de pge2, 16,16-dimetil pge2, ou seu análogo |
| JP6106688B2 (ja) | 2011-12-02 | 2017-04-05 | フェイト セラピューティクス，インコーポレイテッド | 虚血を処置する改善された方法 |
| AU2012321088B8 (en) | 2011-12-02 | 2016-12-15 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| EP2968416A4 (en) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
| JP6713147B2 (ja) | 2014-01-24 | 2020-06-24 | アーエム−ファルマ ベー．フェー．ＡＭ−Ｐｈａｒｍａ Ｂ．Ｖ． | アルカリホスファターゼの下流プロセシング |
| JP6940949B2 (ja) | 2014-01-24 | 2021-09-29 | アーエム−ファルマ ベー．フェー．ＡＭ−Ｐｈａｒｍａ Ｂ．Ｖ． | キメラアルカリホスファターゼ様タンパク質 |
| US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
| CN112481211B (zh) | 2015-01-26 | 2024-07-05 | 儿童医院公司 | 免疫调节性提高的细胞及其使用和生产方法 |
| EP3307747A4 (en) | 2015-06-12 | 2019-02-27 | Simon Fraser University | AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF |
| JP2018520688A (ja) | 2015-07-21 | 2018-08-02 | ザ チルドレンズ メディカル センター コーポレーション | Ｐｄ−ｌ１発現造血幹細胞およびその使用 |
| US11326183B2 (en) | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
| RU2021103425A (ru) | 2016-02-12 | 2021-02-25 | Блубёрд Био, Инк. | Композиции, повышающие число копий вектора (чкв), и способы их применения |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| WO2021224633A1 (en) | 2020-05-06 | 2021-11-11 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066692A (en) | 1972-10-30 | 1978-01-03 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
| US3991087A (en) | 1973-12-13 | 1976-11-09 | Merck & Co., Inc. | 8-Halo-11,12-secoprostaglandins |
| SE7414770L (da) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
| DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
| US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
| US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
| US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
| US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
| US4112236A (en) | 1977-04-04 | 1978-09-05 | Merck & Co., Inc. | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins |
| US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| US5716835A (en) | 1994-05-05 | 1998-02-10 | Allergan, Inc. | Nucleic acid encoding a novel human EP prostaglandin receptor |
| US5807895A (en) * | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
| AU7349298A (en) | 1997-06-23 | 1999-01-04 | Pfizer Inc. | Prostaglandin agonists |
| SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
| US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
| US6586468B1 (en) * | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
| CA2332427A1 (en) * | 1999-03-16 | 2000-09-21 | Toray Industries, Inc. | Prostaglandin ep4 receptor agonist and treatment method |
-
2001
- 2001-01-25 DK DK01300690T patent/DK1132086T3/da active
- 2001-01-25 EP EP01300690A patent/EP1132086B1/en not_active Expired - Lifetime
- 2001-01-25 DE DE60120007T patent/DE60120007T2/de not_active Expired - Fee Related
- 2001-01-25 ES ES01300690T patent/ES2263557T3/es not_active Expired - Lifetime
- 2001-01-25 IL IL14112001A patent/IL141120A0/xx unknown
- 2001-01-25 AT AT01300690T patent/ATE327751T1/de not_active IP Right Cessation
- 2001-01-25 PT PT01300690T patent/PT1132086E/pt unknown
- 2001-01-29 CA CA002332687A patent/CA2332687A1/en not_active Abandoned
- 2001-01-29 US US09/771,164 patent/US6610719B2/en not_active Expired - Fee Related
- 2001-01-29 PE PE2001000097A patent/PE20011048A1/es not_active Application Discontinuation
- 2001-01-30 AU AU16722/01A patent/AU774569B2/en not_active Ceased
- 2001-01-30 HU HU0100495A patent/HUP0100495A3/hu unknown
- 2001-01-30 JP JP2001021534A patent/JP3839261B2/ja not_active Expired - Fee Related
- 2001-01-30 NZ NZ509632A patent/NZ509632A/xx unknown
- 2001-01-30 ZA ZA200100827A patent/ZA200100827B/xx unknown
- 2001-01-31 CO CO01007013A patent/CO5261529A1/es not_active Application Discontinuation
- 2001-01-31 KR KR10-2001-0004590A patent/KR100419684B1/ko not_active IP Right Cessation
-
2006
- 2006-02-24 JP JP2006047746A patent/JP2006182788A/ja active Pending
- 2006-07-04 CY CY20061100920T patent/CY1105299T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0100495A2 (en) | 2002-10-28 |
| AU1672201A (en) | 2001-08-02 |
| CA2332687A1 (en) | 2001-07-31 |
| KR20010078209A (ko) | 2001-08-20 |
| IL141120A0 (en) | 2002-02-10 |
| US20010041729A1 (en) | 2001-11-15 |
| AU774569B2 (en) | 2004-07-01 |
| DK1132086T3 (da) | 2006-08-28 |
| CO5261529A1 (es) | 2003-03-31 |
| JP2001233792A (ja) | 2001-08-28 |
| ES2263557T3 (es) | 2006-12-16 |
| EP1132086A3 (en) | 2002-01-09 |
| KR100419684B1 (ko) | 2004-02-21 |
| JP3839261B2 (ja) | 2006-11-01 |
| HUP0100495A3 (en) | 2003-12-29 |
| EP1132086A2 (en) | 2001-09-12 |
| NZ509632A (en) | 2003-01-31 |
| DE60120007T2 (de) | 2006-11-16 |
| DE60120007D1 (de) | 2006-07-06 |
| HU0100495D0 (en) | 2001-03-28 |
| PE20011048A1 (es) | 2001-10-19 |
| ATE327751T1 (de) | 2006-06-15 |
| US6610719B2 (en) | 2003-08-26 |
| CY1105299T1 (el) | 2010-03-03 |
| EP1132086B1 (en) | 2006-05-31 |
| PT1132086E (pt) | 2006-09-29 |
| JP2006182788A (ja) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200100827B (en) | Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure. | |
| HK1058934A1 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
| EA200300387A1 (ru) | Ингибиторы рецептора ep4 для лечения ревматоидного артрита | |
| WO2004069792A3 (en) | Quinoline-derived amide modulators of vanilloid vr1 receptor | |
| EE200300246A (et) | EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks | |
| BG102726A (en) | Combined therapy for osteoporosis | |
| DK1225881T3 (da) | Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion | |
| EP1108426A3 (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence | |
| NO20033959D0 (no) | Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon | |
| DE60029242D1 (de) | Arzneien zur begleitenden behandlung von glaukomen | |
| WO2002041894A3 (en) | Selective dopamine d4 receptor agonists for treating sexual dysfunction | |
| BR0008603A (pt) | Método para tratamento de copd | |
| IT1293804B1 (it) | Diarilalchilpiperazine attive sulle basse vie urinarie | |
| PL370842A1 (en) | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | |
| DK1455770T3 (da) | Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser | |
| WO2001035945A3 (en) | Use of prostaglandin a2 for the treatment and prophylaxis of priapism | |
| DE60218024D1 (de) | Neue zusatzstoffe zur verhinderung des verbackens pulverförmiger emulgatoren | |
| ES2188144T3 (es) | Dispositivo para el tratamiento de agua. | |
| BR9908392A (pt) | Uso de antagonistas de d1/d5 para o tratamento de distúrbios obsessivos compulsivos, distúrbios somatofórmicos, distúrbios dissociativos, distúrbios de alimentação, distúrbios de controle de impulsos e autismo | |
| MY155220A (en) | Selective dopamine d4 receptor agonists for treating sexual dysfunction | |
| EP1581759A4 (en) | METHODS OF TREATING TAXOL INDUCED SENSORY NEUROPATHY | |
| EP1374899A4 (en) | REMEDIES FOR POST-TRAUMATIC STRESS DISORDER | |
| WO2002007766A3 (en) | Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia | |
| TH53114A (th) | การรักษาความผิดปกติของไต |